Within about one year of its launch, the product has been implemented in over 180 institutions and more than 17,000 hospital beds, capturing about 80% of the market share.
On Tuesday, Daewoong Pharmaceutical held the “Daewoong Pharmaceutical Innovare Partners Day (Digital Healthcare)” at the B-work venue in Jamsil, Seoul, in collaboration with NAVER and JNPMEDI. The event showcased the achievements of digital healthcare portfolio companies that the three organizations jointly developed and nurtured.
Daewoong Pharmaceutical took the lead by unveiling successful collaboration models between pharmaceutical companies and AI healthcare startups, highlighting its partnership with SEERS and its Digital No.1 Strategy. This marks the first public disclosure of specific achievements in this area.
Oh Chang Heon, head of the Digital Healthcare Division, noted that the medical landscape is evolving from reactive treatment to proactive disease prediction and prevention. He emphasized Daewoong Pharmaceutical’s goal of enhancing patients’ quality of life by creating a comprehensive healthcare ecosystem that spans the entire patient journey—from prevention and early diagnosis to treatment and aftercare—extending beyond mere pharmaceutical provision.
Daewoong Pharmaceutical is collaborating with Seers Technology on two key projects: mobiCARE, a wearable electrocardiogram testing solution, and thynC, an AI-powered bed monitoring system.
Oh highlighted the rapid growth of these solutions in the digital healthcare market. He reported that mobiCARE, which began collaboration in 2020, now conducts about 40,000 tests monthly, achieving a 70% market share in reimbursable tests alone. ThynC, launched just a year ago, has been adopted by over 180 institutions and more than 17,000 hospital beds, securing around 80% of the market share. This rapid adoption outpaces major competitors, whose products typically cover only 2,000 to 3,000 beds.
He attributed Daewoong Pharmaceutical’s success in digital healthcare discovery and investment to three key factors: differentiated technology and products that meet customer needs, sales and marketing expertise, and strengthened market entry barriers through continuous product enhancement.
Illustrating their differentiated technology, Oh pointed out that mobiCARE’s lightweight wearable design significantly improves patient comfort and compliance during testing. He added that thynC offers unique features, such as fall-detection alarms, setting it apart from competitors.
To further differentiate their services, the company pioneered a recharge product and delivery service for mobiCARE, streamlining the process by eliminating the need for patients to return devices to hospitals. This innovation allows healthcare professionals to receive devices, collect data, and refurbish them more efficiently.
Oh also emphasized their strategies for securing insurance reimbursement and expanding into the screening market. He identified obtaining insurance coverage as a critical factor for the rapid market growth of new products. The company has actively engaged with relevant academic societies to advocate for reimbursement. Additionally, they’ve tapped into the screening market, which serves about 17 million annual participants, creating new revenue streams beyond traditional hospital sales.
Oh reported that through mobiCARE and thynC, they are documenting and promoting various cases of sudden cardiac death prevention, reinforcing their brand value. Looking ahead, he outlined Daewoong Pharmaceutical’s vision to establish a 24-hour health-monitoring system that links hospitals and homes. This data-driven healthcare ecosystem aims to provide healthcare professionals with more precise evidence for treatment while offering patients a safer, more proactive health management experience.
Subsequent sessions at the event featured corporate presentations on platforms, brain health, and aging. The first session included Puzzle AI and iKooB, who presented platform-centric strategies such as voice-based EMR and real-time blood glucose monitoring. The second session showcased innovations in brain health from Emocog, Sylvia Health, Voinosis, and Nanophilia, including digital therapeutic devices for mild cognitive impairment, voice-based dementia diagnosis, and cognitive health management solutions. The third session featured EXOSYSTEMS Inc., TR, MEDI-IoT, and Healcerion, who outlined business expansion strategies focused on licensing and joint marketing collaborations. The event concluded with one-on-one deep dive meetings between companies and investors.